→ bmka:Pre-clinical development of a new drug is the most 12/21 09:57
→ bmka:expensive part, very very high investment with low output 12/21 09:58
→ bmka:It's sometimes pure luck to find something. 12/21 09:58
→ bmka:It's a great opportuinity that 宇昌 gets to continue 12/21 10:02
→ bmka:moving TNX 355 forward. In hind sight, passing phase II 12/21 10:03
→ bmka:is pretty good, if you start with 1000 compound, perhaps 12/21 10:03
→ bmka:only 5 get to pass phase I! 12/21 10:03
推 echo:回樓上 Preclinical is the MOST expensive part? R U SURE? 12/21 11:27
→ echo:Do you know how much it takes for an P1 study? 12/21 11:27
→ Shilia:如果要用到靈長類動物做 pre-clinical 的話，要說那會變成 12/21 11:44
→ Shilia:最昂貴的部份我想是有可能的。不過如果像是做抗肥胖藥物這 12/21 11:45
→ Shilia:種，應該還是人體試驗時開銷最是令人驚嚇.. 12/21 11:46
推 echo:不管哪種藥，臨床試驗的費用會遠遠大過臨床前/非臨床試驗費用 12/21 12:58
→ puec2:有人既然護航護到這邊來了 12/21 18:53
→ puec2:他說的應該是全人類投資在針對某個疾病的研究上的investment 12/21 18:55
→ puec2:我們講得是針對單一藥物實驗室開發的成本。 12/21 18:55
→ echo:"不管是哪一個單一藥品"，臨床試驗都是最貴的~ 12/21 20:03
→ bmka:I don't think p1 is more expensive than p3, as it usually 12/21 21:17
→ bmka:at most a couple dozens of subjects. On the other hand, p 12/21 21:19
→ bmka:usually requires hundreds or thousands of subjects. 12/21 21:20
→ bmka:However, the chance of reaching p3 is very low..... 12/21 21:21
→ bmka:Oops, I misunderstood echo's comments. 12/21 21:28
→ Shilia:"有人既然護航護到這邊來了" ← 我從來就不是國衛院離家出 12/21 22:04
→ Shilia:走的智慧財產！ 12/21 22:05
→ Shilia:中裕新藥曾經開過做臨床前毒理試驗和藥物動力學的缺，那是 12/21 22:07
→ Shilia:我認識這個藥這家公司這個 HIV/AIDS project 的原因。 12/21 22:08
→ Shilia:puec2 先生你絕對會比較高興我不要繼續講國衛院的事情的！ 12/21 22:10
→ puec2:我可不是在講你喔 推文看清楚吧 12/21 23:58